María Victoria
Mateos Manteca
Profesora Titular de Universidad
Hadassah Medical Center
Jerusalén, IsraelPublicaciones en colaboración con investigadores/as de Hadassah Medical Center (5)
2020
-
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573
2016
-
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Blood, Vol. 128, Núm. 9, pp. 1174-1180
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Drugs, Vol. 76, Núm. 8, pp. 853-867
2015
-
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152